S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
NASDAQ:ECYT

Endocyte (ECYT) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$23.99
$23.99
50-Day Range
N/A
52-Week Range
$2.81
$24.00
Volume
N/A
Average Volume
2.12 million shs
Market Capitalization
$1.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ECYT stock logo

About Endocyte (NASDAQ:ECYT) Stock

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.

Receive ECYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Endocyte and its competitors with MarketBeat's FREE daily newsletter.

ECYT Stock News Headlines

The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty
A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty
A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.
See More Headlines

Receive ECYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Endocyte and its competitors with MarketBeat's FREE daily newsletter.

ECYT Company Calendar

Last Earnings
11/07/2018
Today
5/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:ECYT
CUSIP
29269A10
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-55,060,000.00
Net Margins
-32,296.09%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$70,000.00
Price / Sales
28,133.42
Book Value
$1.99 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.97 billion
Optionable
Optionable
Beta
-0.01

Key Executives

  • Mr. Michael A. Sherman (Age 52)
    CEO, Pres & Director
  • Mr. Michael T. Andriole (Age 45)
    Chief Financial Officer
  • Dr. Alison A. Armour (Age 54)
    Chief Medical Officer
  • Dr. Christopher P. Leamon (Age 52)
    VP of R&D
  • Dr. Philip S. Low (Age 70)
    Co-Founder, Chief Science Officer & Director













ECYT Stock - Frequently Asked Questions

How were Endocyte's earnings last quarter?

Endocyte, Inc. (NASDAQ:ECYT) released its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. The biopharmaceutical company earned $0.09 million during the quarter, compared to analyst estimates of $0.02 million. Endocyte had a negative net margin of 32,296.09% and a negative trailing twelve-month return on equity of 21.19%.

What other stocks do shareholders of Endocyte own?
What is Endocyte's stock symbol?

Endocyte trades on the NASDAQ under the ticker symbol "ECYT."

What is Endocyte's stock price today?

One share of ECYT stock can currently be purchased for approximately $23.99.

How much money does Endocyte make?

Endocyte (NASDAQ:ECYT) has a market capitalization of $1.97 billion and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

How can I contact Endocyte?

Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The official website for the company is www.endocyte.com. The biopharmaceutical company can be reached via phone at 765-463-7175.

This page (NASDAQ:ECYT) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -